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BACKGROUND
Prevention of reinfection and resurgence is an integral component of the goal to 
eradicate malaria. However, the adverse effects of malaria resurgences are not 
known.
METHODS
We assessed the prevalence of Plasmodium falciparum infection among 1819 Mozam-
bican women who delivered infants between 2003 and 2012. We used microscopic 
and histologic examination and a quantitative polymerase-chain-reaction (qPCR) 
assay, as well as flow-cytometric analysis of IgG antibody responses against two 
parasite lines.
RESULTS
Positive qPCR tests for P. falciparum decreased from 33% in 2003 to 2% in 2010 and 
increased to 6% in 2012, with antimalarial IgG antibody responses mirroring these 
trends. Parasite densities in peripheral blood on qPCR assay were higher in 2010–
2012 (geometric mean [±SD], 409±1569 genomes per microliter) than in 2003–2005 
(44±169 genomes per microliter, P = 0.02), as were parasite densities in placental 
blood on histologic assessment (50±39% of infected erythrocytes vs. 4±6%, P<0.001). 
The malaria-associated reduction in maternal hemoglobin levels was larger in 
2010–2012 (10.1±1.8 g per deciliter in infected women vs. 10.9±1.7 g per deciliter in 
uninfected women; mean difference, −0.82 g per deciliter; 95% confidence interval 
[CI], −1.39 to −0.25) than in 2003–2005 (10.5±1.1 g per deciliter vs. 10.6±1.5 g per 
deciliter; difference, −0.12 g per deciliter; 95% CI, −0.67 to 0.43), as was the reduc-
tion in birth weight (2863±440 g in women with past or chronic infections vs. 
3070±482 g in uninfected women in 2010–2012; mean difference, −164.5 g; 95% 
CI, −289.7 to −39.4; and 2994±487 g vs. 3117±455 g in 2003–2005; difference, 
−44.8 g; 95% CI, −139.1 to 49.5).
CONCLUSIONS
Antimalarial antibodies were reduced and the adverse consequences of P. falciparum 
infections were increased in pregnant women after 5 years of a decline in the preva-
lence of malaria. (Funded by Malaria Eradication Scientific Alliance and others.)
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The malaria parasite can persist and reappear in areas where infection is no longer circulating or is circulating at very 
low levels.1 Since prevention of reinfection and 
resurgence is an integral component of the cur-
rent goal to eradicate malaria,2 understanding 
the determinants and clinical consequences of 
malaria declines and resurgences, as well as the 
timescales for gain and loss of antimalarial im-
munity, has become a priority.
Malaria is an infectious disease that requires 
boosting to maintain immunity over time3; a re-
duction in parasite exposure can lead to a loss of 
population-level immunity and an increase in the 
harmful effects of malaria infections during re-
surgences.4 Because of the increased susceptibil-
ity to malaria during pregnancy,5 the conse-
quences of a reduction in malaria immunity 
among pregnant women could be particularly 
severe, especially in the context of the human 
immunodeficiency virus (HIV) pandemics in 
Africa,6 which can impair the maintenance of 
effective immune responses.7 However, declining 
malaria transmission among pregnant women8-10 
may have an effect on malaria-related clinical 
outcomes that has not yet been assessed.
In areas where malaria is endemic, antibodies 
against Plasmodium falciparum VAR2CSA11 develop 
in pregnant women. VAR2CSA is a variant sur-
face antigen that mediates placental accumula-
tion of infected erythrocytes12 and leads to the 
deleterious effects on the mothers and their 
offspring, especially in primigravid women.13 
Antibodies against VAR2CSA are acquired after 
exposure to placental parasites in a parity-depen-
dent manner,14 contribute to a reduction in the 
clinical consequences of malaria in pregnancy,15 
and are affected by variables that influence the 
risk of exposure to P. falciparum.16-18 Therefore, 
decreases in this pregnancy-specific immunity 
after reductions in transmission might affect the 
disease burden during resurgences.
Although the relationship between the preva-
lence of malaria among pregnant women and 
the prevalence in the general community is still 
incompletely understood,19 malaria testing in 
pregnant women at health care facilities can 
provide information about the effect of changes 
in malaria transmission on the disease burden. 
To better understand the consequences of malaria 
resurgences, we examined parasitologic, immuno-
logic, and clinical trends among pregnant women 
delivering between 2003 and 2012 in the Manhiça 
District in southern Mozambique.
Me thods
Study Sites and Population
Pregnant women who provided written informed 
consent to participate in two clinical trials of 
antimalarial drugs between 2003 and 200520 and 
between 2010 and 201221,22 at antenatal clinics in 
the Manhiça District were included in the study. 
Biases due to pooling of data from these two 
clinical trials, as well as to changes from the 
earlier to the later period in the health care pro-
vided to the women, were minimized by the use 
of similar protocols and procedures during the 
two trials. The intensity of malaria transmission 
in this region used to be moderate23 and has 
decreased in the past few years, as evidenced by a 
reduction in hospital admissions for malaria. The 
area has been under continuous demographic 
surveillance by the Centro de Investigação em 
Saúde da Manhiça (CISM) since 1996.24
All women included in the study received bed 
nets treated with long-lasting insecticide, as well 
as intermittent preventive treatment during preg-
nancy, which in 2003–2005 consisted of two 
doses of sulfadoxine–pyrimethamine20 and in 
2010–2012 consisted of two doses of mefloquine 
or sulfadoxine–pyrimethamine, if the women were 
HIV-negative,22 or three doses of mefloquine or 
placebo, if they were HIV-positive and were receiv-
ing trimethoprim–sulfamethoxazole prophylaxis.21 
At delivery, maternal hemoglobin was measured 
with the use of a HemoCue or Sysmex KX21 
analyzer, and newborns were weighed (with the 
use of weekly calibrated scales, which were either 
digital scales20 or triple-beam balances21,22). Tissue 
samples from the maternal side of the placenta, 
as well as 50 μl of maternal peripheral-, placen-
tal-, and cord-blood samples on filter papers, 
were collected for parasitologic assessments. At 
delivery, peripheral blood was collected into EDTA 
vacutainers and centrifuged, with the plasma 
stored at −20°C. Clinical malaria episodes were 
treated according to national guidelines at the time 
of the study, and parenteral quinine was admin-
istered for severe malaria. The study protocols 
and informed-consent forms were reviewed and 
approved by the National Ethics Review Commit-
tee of Mozambique and the Ethics Review Com-
mittee of the Hospital Clinic of Barcelona.
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Parasitologic Assessments
Thick and thin blood films, as well as placental-
biopsy samples in 10% neutral buffered forma-
lin, were assessed for detection of plasmodium 
species according to standard, quality-controlled 
procedures.25-27 A random selection of 50% of 
the peripheral-blood samples (958 samples) and 
placental-blood samples (941) on filter papers 
was used for detection of P. falciparum in duplicate 
by means of a real-time quantitative polymerase-
chain-reaction (qPCR) assay targeting 18S ribo-
somal RNA (rRNA)28 (see the Methods section in 
the Supplementary Appendix, available with the 
full text of this article at NEJM.org).
Measurement of Antimalarial IgG Antibodies
A random selection of 35% of the peripheral-
blood plasma samples (654 samples) collected at 
delivery was used for flow-cytometric measure-
ment of IgG16 (expressed as mean fluorescence 
intensity [MFI]) against a chondroitin sulfate 
A–binding parasite line expressing VAR2CSA 
(CS2), indicating pregnancy-specific antimalarial 
immunity,29 and a rosetting parasite line (R29), 
indicating general antimalarial immunity30 (see 
the Methods section in the Supplementary Ap-
pendix). The P. falciparum CS2 (MRA-96) labora-
tory strain was obtained through the Malaria 
Research and Reference Reagent Resource Cen-
ter (MR4) as part of the BEI Resources Reposi-
tory, National Institute of Allergy and Infectious 
Diseases, National Institutes of Health.
Study Definitions
Pregnant women were included in the analysis if 
they received sulfadoxine–pyrimethamine, meflo-
quine, or trimethoprim–sulfamethoxazole, alone 
or in combination with mefloquine, during preg-
nancy and if all information was available on the 
date of delivery, HIV status, age, and parity, as 
well as results of peripheral-blood microscopic 
examination and placental histologic assessment. 
Women were classified a priori as primigravid 
(first pregnancy) or multigravid (at least one pre-
vious pregnancy), and age was categorized as 
younger than 20 years, 20 to 24 years, or 25 
years of age or older.16,17 Maternal microscopic 
infection at delivery was defined as the presence 
of P. falciparum parasites in peripheral blood or in 
the placenta on either microscopic or histologic 
examination, qPCR-positive infection was defined 
as a positive result of qPCR testing in peripheral 
or placental blood, and submicroscopic infection 
was defined as the presence of malaria parasites 
on qPCR testing but not on microscopic examina-
tion. Past placental infection was defined by the 
presence of malaria pigment (i.e., hemozoin27) 
without parasite detection on placental histo-
logic examination, and chronic placental infec-
tion was defined by the presence of malaria 
pigment in combination with the detection of 
parasites.
Statistical Analysis
Our primary hypothesis was that declines in the 
prevalence of malaria would be associated with 
reductions in antimalarial immunity, and our 
secondary hypothesis was that reduced immu-
nity would lead to higher parasite densities, 
smaller differences in parasite densities and 
antibody levels between primigravid and multi-
gravid women, and a larger adverse effect of 
malaria. Proportions were compared by means 
of Fisher’s exact test, and continuous variables 
by means of Student’s t-test. The primary out-
come variables — maternal microscopic infec-
tion and level of IgG antibodies against CS2 — 
were compared between the two study periods 
(2003–2005 and 2010–2012) with the use of 
logistic- and linear-regression models, respective-
ly, adjusted according to parity, age, and HIV 
infection status. Secondary variables included 
qPCR positivity for maternal infection, peripheral-
blood and placental infections, submicroscopic 
infections, and levels of IgG antibodies against 
R29, as well as data according to year, with 
observations from 2003 and 2004 combined 
because of the small sample in 2003 (28 obser-
vations) and with the use of the first year of the 
second period (2010) as the reference year for 
comparisons. To test the secondary hypothesis, 
we used linear regression to analyze the effect of 
study period on log-transformed parasite densi-
ties, as well as the effect of malaria on maternal 
hemoglobin levels and newborn weight in each 
of the two periods. To determine whether a 
modification of the associations with parity was 
attributable to the study period, we included an 
interaction term in the regression models and 
assessed separately the effect of parity for each 
period. The data were analyzed with the use of 
Stata software, version 11.0 (Stata). P values of less 
than 0.05 were considered to indicate statistical 
significance for primary outcomes, with Bonfer-
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roni corrections applied for the secondary out-
come variables tested.
R esult s
Study Population
A total of 2259 women received bed nets treated 
with long-lasting insecticide and were given pro-
phylaxis with sulfadoxine–pyrimethamine, meflo-
quine, or trimethoprim–sulfamethoxazole, alone 
or in combination with mefloquine, in the con-
text of the two clinical trials of intermittent 
preventive treatment of malaria in pregnancy 
that were conducted in Manhiça.20-22 Of these 
women, 440 were excluded because of missing 
data on HIV status, peripheral-blood micro-
scopic examination, or placental histologic ex-
amination (Fig. S1 and Table S1 in the Supple-
mentary Appendix). The 1819 women included in 
this study delivered between October 27, 2003, 
and August 14, 2012, and were similar in terms 
of baseline characteristics with all 2259 women 
participating in the randomized trials (Table S1 
in the Supplementary Appendix), as were women 
in both study periods (Table 1).
Trends in Malaria during Pregnancy
The prevalence of maternal microscopic infection 
at delivery (primary outcome) decreased from 
11% in 2003–2005 to 2% in 2010–2012 (Table 1) 
(adjusted odds ratio, 0.19; 95% confidence inter-
val [CI], 0.12 to 0.30; P<0.001). Similar decreases 
were observed in secondary parasitologic out-
comes (P<0.001 in all cases) (Table 1). Micro-
scopic examination of peripheral blood and histo-
logic examination of the placenta, as compared 
with qPCR testing, are described in Table S2 in 
the Supplementary Appendix. The prevalence of 
peripheral-blood infections that were submicro-
scopic was higher during the 2003–2005 period 
than during the 2010–2012 period (70% [26 of 37 
infections] vs. 47% [14 of 30]; adjusted odds ra-
tio, 3.81; 95% CI, 1.17 to 12.46; P = 0.03).
Secondary analysis by year showed that the 
prevalence of microscopic maternal infection 
decreased from 12% in 2003–2004 to 1% in 2010 
(P<0.001, adjusted), and the prevalence of qPCR-
positive maternal infection decreased from 33% 
to 2% (P<0.001, adjusted), with increases in 
2012 to 4% for microscopic infections (P = 0.003, 
adjusted) and to 6% for qPCR-positive infections 
(P = 0.03, adjusted) (Fig. 1, and Fig. S2 in the 
Supplementary Appendix). Similar trends were 
observed after the exclusion of women who re-
ceived mefloquine as intermittent preventive 
treatment of malaria during pregnancy in the 
2010–2012 period (Table S3 in the Supplemen-
tary Appendix). Cord-blood microscopic infec-
tions were consistently low (≤1%) throughout 
the study period.
Antimalarial Immunity
Geometric mean levels of IgG against CS2 (pri-
mary outcome) were lower in 2010–2012 than in 
2003–2005 (Table 1) (adjusted ratio, 0.44; 95% 
CI, 0.36 to 0.54; P<0.001), with similar reduc-
tions observed for IgG antibodies against R29 
(adjusted ratio, 0.43; 95% CI, 0.33 to 0.58; 
P<0.001). Secondary analysis by year showed that 
IgG levels decreased from 2003 to 2010 and 
gradually increased between 2010 and 2012 
(Fig. 2). Maternal qPCR-positive infections at 
delivery were associated with an increase in IgG 
levels against CS2 (P<0.001, adjusted) but not 
against R29 (P = 0.30, adjusted) (Fig. S3 in the 
Supplementary Appendix).
Parasite Densities and Clinical Outcomes
Parasite densities in peripheral blood on qPCR 
assay were higher in 2010–2012 (geometric mean 
[±SD], 409±1569 genomes per microliter) than 
in 2003–2005 (44±169 genomes per microliter, 
P = 0.02), as were parasite densities in placental 
blood on histologic examination (50±39% of 
infected erythrocytes vs. 4±6%, P<0.001) (Fig. 3). 
Similar increases in parasite densities, although 
not significant, were observed by means of mi-
croscopic examination in peripheral blood and 
qPCR assay in placental blood. Parasite densities 
quantified by means of microscopic examina-
tion in cord blood were also higher in 2010–2012 
(geometric mean, 38,249±65,809 parasites per 
microliter) than in 2003–2005 (208±551 para-
sites per microliter; P = 0.046; P = 0.23 after Bon-
ferroni correction).
The average maternal hemoglobin concentra-
tion increased slightly from 2003–2005 to 2010–
2012, although no difference was observed in 
mean newborn weight (Table 1). A larger reduction 
in hemoglobin levels associated with microscopic 
maternal infections was observed in 2010–2012 
(10.1±1.8 g per deciliter in infected women vs. 
10.9±1.7 g per deciliter in uninfected women; 
mean difference, −0.82 g per deciliter; 95% CI, 
−1.39 to −0.25; P = 0.005, adjusted; P = 0.01 af-
ter Bonferroni correction) than in 2003–2005 
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Variable
2003–2005 
(N = 374)
2010–2012 
(N = 1445) P Value
Year — no. (%)
2003 28 (7) 0
2004 232 (62) 0
2005 114 (30) 0
2010 0 358 (25)
2011 0 803 (56)
2012 0 284 (20)
IPTp — no. (%)†
Sulfadoxine–pyrimethamine 374 (100) 324 (22)
Mefloquine 0 894 (62)
Trimethoprim–sulfamethoxazole 0 227 (16)
HIV status — no. (%)‡
Negative 274 (73) 998 (69)
0.13
Positive 100 (27) 447 (31)
CD4+ T-cell count at recruitment — per mm3§ 526.8±237.3 462.9±255.7 0.13
Parity — no. (%)
Primigravid 113 (30) 422 (29)
0.70
Multigravid 261 (70) 1023 (71)
Age — no. (%)
<20 yr 129 (34) 458 (32)
0.0820–24 yr 106 (28) 358 (25)
≥25 yr 139 (37) 629 (44)
Maternal hemoglobin — g/dl 10.5±1.5 10.8±1.7 0.02¶
Newborn birth weight — g 3055±473 3061±480 0.80
Primary outcomes
Maternal microscopic infection — no. (%)‖ 41 (11) 33 (2) <0.001¶
IgG antibodies against CS2, geometric mean ±SD — MFI** 6055±8742 3001±3319 <0.001¶
Secondary outcomes
Maternal qPCR-positive infection — no./total no. (%)†† 50/165 (30) 33/753 (4) <0.001¶
Peripheral-blood infection on microscopic assessment — no./
total no. (%)
25/374 (7) 32/1445 (2) <0.001¶
Peripheral-blood infection on qPCR testing — no./total no. (%) 37/169 (22) 30/789 (4) <0.001¶
Active placental infection on histologic assessment — no./total 
no. (%)
37/374 (10) 18/1445 (1) <0.001¶
Past or chronic placental infection on histologic assessment — 
no./total no. (%)
179/374 (48) 57/1445 (4) <0.001¶
Placental-blood infection on qPCR testing — no./total no. (%) 39/165 (24) 27/776 (3) <0.001¶
IgG antibodies against R29, geometric mean ±SD — MFI** 7820±9139 3610±5859 <0.001¶
*  Plus–minus values are means ±SD unless otherwise noted. Dates of sample collection were as follows: 2003, October 
27 through December 31; 2004, January 1 through December 26; 2005, January 1 through October 7; 2010, March 28 
through December 31; 2011, January 1 through December 31; and 2012, January 1 through August 14. Percentages 
may not sum to 100 because of rounding. qPCR denotes quantitative polymerase chain reaction.
†  IPTp denotes intermittent preventive treatment during pregnancy, with mefloquine given alone or in combination 
with trimethoprim–sulfamethoxazole.
‡  Maternal human immunodeficiency virus (HIV) status was determined with the use of the Determine HIV-1/2 test 
(Abbott Laboratories) and was confirmed by means of the Uni-Gold HIV Rapid Test (Trinity Biotech).
§  CD4+ T-cell counts were performed in BD Trucount tubes (BD Biosciences).
¶  The P value is significant according to multivariate analysis adjusted for HIV status, parity, and age.
‖  Maternal microscopic infection was defined by the presence of P. falciparum parasites in peripheral blood or in the 
placenta on microscopic or histologic examination, respectively.
**  MFI (mean fluorescence intensity) was measured in arbitrary fluorescence units.
††  Maternal qPCR-positive infection was defined by a positive result on qPCR testing in peripheral or placental blood.
Table 1. Characteristics of Study Participants and Parasitologic, Immunologic, and Clinical Outcomes, According to 
Study Period.*
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(10.5±1.1 g per deciliter vs. 10.6±1.5 g per deci-
liter; mean difference, −0.12 g per deciliter; 95% 
CI, −0.67 to 0.43; P = 0.67, adjusted). Similarly, 
past or chronic placental infections, which have 
been shown to lead to low birth weight because 
of fetal growth restriction,5 were associated with 
larger reductions in the weight of newborns dur-
ing the 2010–2012 period (2863±440 g in infected 
women vs. 3070±482 g in uninfected women; 
mean difference, −164.5 g; 95% CI, −289.7 to 
−39.4; P = 0.01, adjusted; P = 0.02 after Bonferroni 
correction) than during the 2003–2005 period 
(2994±487 g vs. 3117±455 g; mean difference, 
−44.8 g; 95% CI, −139.1 to 49.5; P = 0.35, adjusted).
Figure 1. Prevalence of Plasmodium falciparum Infection among Pregnant Women at Delivery, According to Year.
Panel A shows the prevalence of infection on the basis of microscopic assessment, histologic assessment, or both, 
and Panel B shows the prevalence on the basis of quantitative polymerase-chain-reaction (qPCR) testing. Maternal 
infection was defined by the detection of P. falciparum in either peripheral blood or the placenta. Results of qPCR 
testing of both peripheral and placental blood were available for 918 women. Observations from 2003 (28 for micro-
scopic assessment, histologic assessment, or both and 14 for qPCR testing) and 2004 (232 for microscopic assess-
ment, histologic assessment, or both and 68 for qPCR testing) were combined because of the small sample in 2003. 
P values are based on a multivariate analysis adjusted for human immunodeficiency virus (HIV) status, parity, and 
age. T bars represent standard errors.
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Figure 2. IgG Antibodies against Two P. falciparum Lines in Pregnant Women at Delivery, According to Year.
Panel A shows IgG antibodies, expressed as mean fluorescence intensity (MFI, measured in arbitrary fluorescence 
units), against a chondroitin sulfate A–binding parasite line (CS2), and Panel B shows MFI for IgG antibodies against 
a rosetting parasite line (R29). I bars represent geometric means plus 95% confidence intervals. Dashed lines indi-
cate the mean plus 3 SD from the negative control values. P values are based on a multivariate analysis adjusted for 
HIV status, parity, and age.
2003–
2004
2005 2010 2011 2012
M
FI
 (a
rb
itr
ar
y 
un
its
)
M
FI
 (a
rb
itr
ar
y 
un
its
)
105
104
102
103
105
104
102
103
2003–
2004
2005 2010 2011 2012
B IgG Antibodies against R29A IgG Antibodies against CS2
P<0.001 P=0.007 P<0.001 P=0.01
N=67 N=79 N=177 N=253 N=78 N=67 N=79 N=177 N=253 N=78
The New England Journal of Medicine 
Downloaded from nejm.org on January 29, 2016. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med 373;17 nejm.org October 22, 2015 1613
P. falciparum Burden, Immunity, and Disease in Pregnancy
Effect of Parity on Parasitologic  
and Immunologic Outcomes
The relationship of parity to parasite density, 
submicroscopic infections, and IgG levels dif-
fered between the two study periods. In the 
2003–2005 period, higher parity was associated 
with a decrease in parasite densities in periph-
eral blood on microscopic examination and 
qPCR testing, as well as in placental blood on 
qPCR testing (Table 2). In contrast, parasite den-
sities were similar between primigravid and 
multigravid women in the 2010–2012 period. 
The prevalence of peripheral-blood infections 
that were submicroscopic was higher among 
multigravid women (87% [20 of 23 infections]) 
than among primigravid women (43% [6 of 14], 
P = 0.008) in 2003–2005 but was similar in pri-
migravid women and multigravid women (38% 
[3 of 8 infections] and 50% [11 of 22], respec-
tively; P = 0.55) in 2010–2012. Finally, the in-
crease in levels of pregnancy-specific IgG anti-
bodies (i.e., IgG antibodies against CS2 parasites) 
with increasing parity was more marked among 
women delivering in 2003–2005 (adjusted ratio 
of mean MFI in multigravid women to mean 
MFI in primigravid women, 4.38; 95% CI, 2.30 
to 8.36; P<0.001) than among those delivering in 
2010–2012 (adjusted ratio of mean MFI, 1.49; 
95% CI, 1.11 to 2.01; P = 0.009) (Table 2), with 
similar results for the level of IgG antibodies 
against DBL3X and DBL5ε from VAR2CSA (Table 
S4 in the Supplementary Appendix). No parity 
effect was observed for levels of IgG antibodies 
against R29.
Figure 3. P. falciparum Densities in Pregnant Women Infected at Delivery, According to Study Period.
Results are shown for microscopic assessment of peripheral blood (Panel A), histologic assessment of the placenta 
(Panel B; lower limit of quantification, ≤1%), and qPCR testing of peripheral and placental blood (Panels C and D, 
respectively). For Panels C and D, the lower limit of quantification was 2 genomes per microliter, which was the num-
ber assigned if qPCR amplification was observed outside the lower range of the standard curve (i.e., 5 genomes per 
microliter). I bars represent geometric means plus 95% confidence intervals. P values are based on a multivariate 
analysis adjusted for HIV status, parity, and age.
2003–2005 2010–2012
Er
yt
hr
oc
yt
es
 (%
 in
fe
ct
ed
)
Pa
ra
si
te
s 
(n
o.
/µ
l)
102
101
10−1
100
105
106
104
101
103
102
2003–2005 2010–2012
B Placenta, Histologic AssessmentA Peripheral Blood, Microscopic Assessment
D Placental Blood, qPCRC Peripheral Blood, qPCR
P=0.29 P<0.001
N=25 N=32 N=37 N=18
2003–2005 2010–2012
G
en
om
es
 (n
o.
/µ
l)
G
en
om
es
 (n
o.
/µ
l)
106
104
100
103
105
101
102
106
104
100
103
105
101
102
2003–2005 2010–2012
P=0.009 P=0.10
N=37 N=30 N=39 N=27
The New England Journal of Medicine 
Downloaded from nejm.org on January 29, 2016. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med 373;17 nejm.org October 22, 20151614
T h e  n e w  e ngl a nd  j o u r na l  o f  m e dic i n e
Ta
bl
e 
2.
 D
en
si
tie
s 
of
 P
. f
al
ci
pa
ru
m
 a
nd
 L
ev
el
s 
of
 Ig
G
 A
nt
ib
od
ie
s 
ag
ai
ns
t P
. f
al
ci
pa
ru
m
 L
in
es
, A
cc
or
di
ng
 to
 S
tu
dy
 P
er
io
d 
an
d 
Pa
ri
ty
.*
O
ut
co
m
e
20
03
–2
00
5
20
10
–2
01
2
P 
V
al
ue
 fo
r 
In
te
ra
ct
io
n†
Pr
im
ig
ra
vi
d
M
ul
tig
ra
vi
d
P 
V
al
ue
Pr
im
ig
ra
vi
d
M
ul
tig
ra
vi
d
P 
V
al
ue
no
. o
f 
pa
tie
nt
s
ge
om
et
ric
 
m
ea
n
no
. o
f 
pa
tie
nt
s
ge
om
et
ric
 
m
ea
n
no
. o
f 
pa
tie
nt
s
ge
om
et
ric
 
m
ea
n
no
. o
f 
pa
tie
nt
s
ge
om
et
ric
 
m
ea
n
Pa
ra
si
te
 d
en
si
ty
 in
 th
e 
pl
ac
en
ta
H
is
to
lo
gi
c 
as
se
ss
m
en
t (
%
 o
f 
in
fe
ct
ed
 e
ry
th
ro
cy
te
s)
20
5.
9±
8.
4
17
2.
5±
3.
2
0.
06
9
47
.7
±4
3.
8
9
51
.8
±3
3.
9
0.
83
0.
18
qP
C
R 
te
st
in
g 
(n
o.
 o
f g
en
om
es
/μ
l)
13
85
7.
3±
41
46
.1
26
13
.2
±4
4.
4
0.
00
3‡
12
20
0.
9±
78
6.
2
15
15
48
.4
±6
78
7.
2
0.
22
0.
00
4
Pa
ra
si
te
 d
en
si
ty
 in
 p
er
ip
he
ra
l 
bl
oo
d
M
ic
ro
sc
op
ic
 a
ss
es
sm
en
t (
no
. 
of
 p
ar
as
ite
s/
μl
)
15
13
,8
25
.6
±1
7,
87
9.
4
10
63
1.
9±
12
28
.5
<0
.0
01
15
42
69
.0
±1
3,
24
8.
4
17
10
,6
47
.9
±1
8,
04
7.
6
0.
30
0.
00
1
qP
C
R 
te
st
in
g 
(n
o.
 o
f g
en
om
es
/μ
l)
14
54
6.
6±
25
40
.5
23
9.
4±
21
.7
<0
.0
01
‡
8
98
8.
3±
42
71
.4
22
29
6.
3±
10
98
.3
0.
46
0.
14
Ig
G
 a
nt
ib
od
ie
s 
(M
FI
)§
C
S2
 p
ar
as
ite
 li
ne
45
23
07
.8
±2
09
7.
3
10
1
93
06
.1
±1
3,
33
6.
6
<0
.0
01
‡
13
1
17
63
.4
±1
19
8.
7
37
6
36
11
.2
±4
20
6.
7
<0
.0
01
‡
0.
00
3
R
29
 p
ar
as
ite
 li
ne
45
83
90
.4
±8
54
5.
1
10
1
75
79
.1
±9
34
6.
3
0.
63
13
1
30
71
.0
±5
15
7.
8
37
6
38
19
.4
±6
11
5.
9
0.
19
0.
13
* 
 Pl
us
–m
in
us
 v
al
ue
s 
ar
e 
ge
om
et
ri
c 
m
ea
ns
 ±
SD
.
†
  P
 v
al
ue
s 
ar
e 
fo
r 
th
e 
in
te
ra
ct
io
n 
be
tw
ee
n 
st
ud
y 
pe
ri
od
 a
nd
 p
ar
ity
. P
 v
al
ue
s 
fo
r 
th
e 
in
te
ra
ct
io
n 
af
te
r 
B
on
fe
rr
on
i c
or
re
ct
io
n 
w
er
e 
as
 fo
llo
w
s:
 P
 =
 0
.0
2 
fo
r 
pl
ac
en
ta
l p
ar
as
ite
 d
en
si
ty
 o
n 
qP
C
R
 
te
st
in
g,
 P
 =
 0
.0
05
 fo
r 
pe
ri
ph
er
al
 p
ar
as
ite
 d
en
si
ty
 o
n 
m
ic
ro
sc
op
ic
 a
ss
es
sm
en
t, 
an
d 
P 
= 
0.
02
 fo
r 
Ig
G
 a
nt
ib
od
ie
s 
ag
ai
ns
t 
th
e 
C
S2
 p
ar
as
ite
 li
ne
.
‡
  T
he
 P
 v
al
ue
 is
 s
ig
ni
fic
an
t 
ac
co
rd
in
g 
to
 a
 m
ul
tiv
ar
ia
te
 a
na
ly
si
s 
ad
ju
st
ed
 fo
r 
H
IV
 s
ta
tu
s,
 p
ar
ity
, a
nd
 a
ge
.
§ 
 M
ea
n 
flu
or
es
ce
nc
e 
in
te
ns
ity
 (
M
FI
) 
w
as
 m
ea
su
re
d 
in
 a
rb
itr
ar
y 
flu
or
es
ce
nc
e 
un
its
.
The New England Journal of Medicine 
Downloaded from nejm.org on January 29, 2016. For personal use only. No other uses without permission. 
 Copyright © 2015 Massachusetts Medical Society. All rights reserved. 
n engl j med 373;17 nejm.org October 22, 2015 1615
P. falciparum Burden, Immunity, and Disease in Pregnancy
Discussion
Substantial declines in the prevalence of malaria 
among Mozambican pregnant women (from 11% 
in 2003–2005 to 2% in 2010–2012 on the basis 
of peripheral-blood microscopic assessment or 
placental histologic assessment, and from 30% 
to 4% on the basis of qPCR assay) were paral-
leled by reductions in levels of antimalarial IgG 
antibodies. These changes over a 10-year period 
were associated with increasing parasite densi-
ties and a larger adverse effect of infection on 
maternal hemoglobin levels and on the weight of 
newborns during the period of low malaria 
prevalence. Taken together, the data suggest that 
a weakening of antimalarial immunity as a re-
sult of infrequent parasite exposure can increase 
the occurrence of high-density infections and 
their harmful effect among women who become 
infected, as well as among their newborns.
The decline in the prevalence of malaria be-
tween 2003 and 2010, which was associated with 
a slight increase in the mean maternal hemoglo-
bin level, is consistent with reductions in other 
areas of sub–Saharan Africa over similar time 
frames,9,10,31,32 suggesting a continent-wide trend 
during this period. Intermittent preventive treat-
ment with mefloquine during pregnancy in a 
number of the women between 2010 and 2012 
was not responsible for the decrease in the 
prevalence of malaria, since similar declines 
were observed when these women were excluded 
from the analysis. Also, the numbers of malaria-
susceptible primigravid women, rates of HIV 
infection, and CD4+ T-cell counts in HIV-infect-
ed women were relatively constant throughout 
the study period, and all the women received bed 
nets treated with a long-lasting insecticide, sug-
gesting that these factors do not fully account 
for the changes observed. The introduction of 
artemisinin-based combination therapies in Mo-
zambique in 2009, together with increasing use 
of intermittent preventive treatment with sulfa-
doxine–pyrimethamine during pregnancy and 
insecticide-treated bed nets, as recommended by 
the World Health Organization in 2005, may 
have contributed to the observed decline in the 
prevalence of malaria, together with socioeco-
nomic development, improved accessibility to 
health care facilities, and continuous conduct of 
clinical trials and other investigations in the study 
area. The increases in prevalence between 2010 
and 2012 without evident changes in malaria-
control efforts suggest that climate factors, as 
well as increasing mosquito and parasite resis-
tance to insecticides and antimalarial agents, 
respectively, may have played a role. Although 
similar trends have been observed in malaria-
related hospital admissions in the area,33 it re-
mains unclear whether health care facility–based 
trends in malaria among pregnant women who 
are targets of intensive preventive measures can 
be extrapolated to the general community.
Levels of IgG antibodies against CS2 para-
sites (pregnancy-specific immunity) and R29 
parasites (general immunity) mirrored changes 
in the prevalence of malaria infection. Moreover, 
levels of IgG antibodies against CS2 were in-
creased in women with qPCR-positive P. falci-
parum infection at delivery.16,17 These results indi-
cate a close relationship between antibody levels 
and the intensity of malaria transmission16-18,34-36 
and suggest that antibodies against VAR2CSA 
may be a marker for cumulative exposure to the 
parasite during pregnancy.19 More important, this 
study shows that 5 years of a marked decline in 
the prevalence of malaria was accompanied by 
reductions in levels of IgG antibodies against 
CS2 parasites by a factor of 2.8 and by reduc-
tions in IgG antibodies against antigens that are 
not specific to pregnancy, as well as by an in-
crease in the geometric mean of parasite densi-
ties and a larger adverse effect of these infec-
tions on maternal hemoglobin levels and the 
weight of newborns. Reduced opportunities to 
acquire immunity during pregnancy because of 
low infection rates may render multigravid 
women as susceptible to malaria as primigravid 
women, as suggested by the similar parasite 
densities and levels of IgG antibodies against 
CS2 in the two groups of women during the 
period of low malaria prevalence. In accordance 
with previous reports on pregnant women9 and 
children37,38 residing in areas where malaria has 
declined substantially, these observations sug-
gest that infrequent parasite exposure can weak-
en immune regulation of parasite density and 
increase the occurrence of adverse clinical out-
comes among women who become infected, as 
well as among their newborns. However, the in-
crease in antibody levels between 2010 and 2012 
after relatively modest increments in the preva-
lence of infection suggests that immunity may 
be regained as exposure increases.
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Our study has several limitations. Although 
similar procedures were followed in both study 
periods, possible confounding factors, such as 
changes in health care (i.e., access to antiretro-
viral agents and prenatal care) and in other 
vectorborne infections, were not measured, and 
we did not control for pooling of data from 
separate cohorts in this study. Moreover, esti-
mates of the prevalence of malaria among 
women undergoing malaria-prevention measures 
at the hospital may not be representative of the 
prevalence in the community at large.
In conclusion, this study shows a rise in 
malaria with increased parasite densities and a 
larger adverse clinical effect after a marked fall 
in the prevalence of malaria and antimalarial 
immunity among pregnant women. These data 
reinforce the importance of sustaining efforts to 
avoid rebounds of malaria associated with re-
ductions in naturally acquired immunity.39
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